Publications:

Plump, D.; Haponil, E.F.; Katz, R.S.; Tipton-Donovan, A.: Primary Adamantinoma of Rib: Thoracic Manifestations of a Rare Bone Tumor. South Med J, March 1986; 79 (3): 352-5.

Berzon, D.M.; Menkes, H.; Dannenberg, A.M. Jr.; Gertner, A.; Terry, P.; Plump, D.; Bromberger-Barnes, B.: Interstitial Fibrosis and Collateral Ventilation. J Appl Physiol, July 1986; 61 (1): 300-3.

Rock, P.; Silverman, H.; Plump, D.; Kecala, Z.; Smith, P.; Michael Jr., Summer, W.: Efficacy and Safety of Naloxone in Septic Shock. Critical Care Med, Jan 1985; 13 (1): 28-33

Plump, D.H.; Haponik, E.F.: Streptococcus Milleri Empyema. South Med J, Oct. 1983; 76 (10): 1321-2.

Presentations:

Response of the Lung Periphery to Arachodonic Acid: Residual Response after Vagal and Cyclocxygenase Blockade, D.H. Plump, R.J. Traystman, H.A. Mendes, A.R. Gertner, B. Bomberger, P.B. Terry and D.M. Berzon, Scientific Session, American Lung Association/American Thoracic Society, Annual Meeting, May 1982

Clinical Chest Rounds; Scientific Session, American Lung Association/American Thoracic Society Annual Meeting, Las Vegas, Nevada, May 10, 1988

Clinical Trials:

A 12-week, treatment, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of once daily indacaterol in patients with chronic obstructive pulmonary disease. [Novartis Pharmaceuticals Corporation], January, 2010, ongoing. Sub-Investigator.

 A randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of  2 doses of Aclidinium Bromide compared with placebo for 12 weeks in patients with moderate to severe, stable chronic obstructive pulmonary disease followed by a 40-week evaluation of the two Aclidinium Bromide doses. [Forest Research Institute, Inc.], November, 2009, ongoing. Principal Investigator.

 A randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150 Fg once daily with open label tiotropium 18 Fg once daily versus open label tiotropium 18 Fg once daily in patients with  moderate-to-severe chronic obstructive pulmonary disease. [Novartis Pharmaceuticals Corporation], April, 2009, ongoing. Principal Investigator.

Material Copyright © 2001 Texas Pulmonary Consultants